When we combined sunitinib with CAIX-targeted RIT, aimed at the vascular bed (sunitinib) and tumor cells ([177Lu]Lu-cG250), overall survival increased, but ultimately tumors recurred in most mice. The gene discussed is CA9; the disease is neoplasm.